Inogen adds med tech vet to board

BEVERLY, Mass. – Inogen has announced that Vafa Jamali will join the company’s board of directors as an independent director effective June 15. As CEO of ZimVie, Jamali led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Prior to ZimVie, he spent nearly 12 years at Covidien and Medtronic, where he most recently served as senior vice president and president of the Respiratory, Gastrointestinal & Informatics division, a $3 billion business that included 10,000 team members across four businesses and 14 manufacturing sites. “We are pleased to welcome Vafa to the board and look forward to benefiting from his unique perspectives,” said Beth Mora, chairperson. “Throughout his many years of leading medical device companies, Vafa has established a track record of driving strategic execution and delivering sustained growth. As we continue advancing our transformation from a single product oxygen company into a diversified respiratory care platform, we believe Vafa’s insight and direction will help guide our management team to execute on its path forward and continue to deliver strong top-line growth and improve profitability.” In connection with Jamali’s appointment, Inogen has entered into a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter (collectively, “Kent Lake”). The agreement includes customary standstill, voting and other provisions.

• Related: Inogen makes three appointments to exec team.